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Constitutive Expression of Epidermal Growth Factor Receptors on
Normal Human Melanocytes
To the Editor:
The ErbB protein family members are typical receptor ty-
rosine kinases triggering a network of signaling pathways
that govern cellular functions ranging from cell division to
cell death, motility, and adhesion (Jorissen et al, 2002). ErbB
receptors are composed of four homologous transmem-
brane proteins that form homo- or heterodimers that have
different signaling capacity (Roskoski, 2004). The ErbB-1
receptor binds epidermal growth factor (EGF) and trans-
forming growth factor with high affinity (Yarden and
Sliwkowski, 2001).
Given two recent studies by Shahbazi et al (2002) and
Stove et al (2003) on the importance of EGF and heregulin/
HER receptor signaling in melanoma development, we
would like to contribute our data of EGF receptor signaling
in normal human melanocytes (NHM), which has become an
area of recent controversy. In contrast to the recent report
by Grahn and Isseroff (2004) in the Journal, our data clearly
show that NHM express the EGF receptor and that tyrosine
kinase-mediated signaling occurs in response to recombin-
ant EGF. In addition, the majority of previous reports argues
for the EGF receptor being expressed on in situ melanoma
and cultured melanoma cells as analyzed by several differ-
ent techniques (Real et al, 1986; de Wit et al, 1992; Ellis
et al, 1992; Mattei et al, 1994; Huang et al, 1996; Ivanov and
Hei, 2005), whereas other investigators have not found this
to be true (Halaban, 2000; Grahn and Isseroff, 2004). To
address EGF receptor expression on NHM, we have used
commercially available epidermal NHM that were devoid of
dermal fibroblasts and keratinocytes (Cat. Nr. C10452, NHM
M2, Promocell, Heidelberg, Germany). The cells were cul-
tured in PMA-free melanocyte growth medium containing
bovine pituitary extract, recombinant basic fibroblast
growth factor, and insulin (Cat. Nr. C24300, Promocell).
NHM were used in the third passage. As PMA or TPA in
melanocyte media are known to alter gene expression, me-
lanocytes, and melanoma cell lines were not exposed to
mitogens in our experiments.
With regard to the report by Grahn and Isseroff, we feel
that immunofluorescence staining using an EGF-receptor
antibody may not be sensitive enough to detect minute re-
ceptor quantities. To overcome this limitation, cultured NHM
were analyzed by immunocytochemistry using a rabbit EGF
receptor (ErbB-1) antibody (Cat. Nr. 2232, Cell Signaling,
New England Biolabs, Frankfurt, Germany) and the APAAP
method, providing signal amplification by several orders of
magnitude (Mirmohammadsadegh et al, 2000). Results re-
vealed positive, albeit low-level staining of the cell mem-
brane and cytoplasmatic staining, which may be because of
receptor endocytosis (data not shown). To demonstrate
EGFR on NHM, total protein extracts were obtained from
untreated and recombinant EGF-treated NHM at various
time points (Fig 1). Western blot analysis using an EGF re-
ceptor antibody clearly indicated that EGF receptors were
present prior to the addition of recombinant EGF in both
NHM and the A375 melanoma cells (kindly provided by M.
Schartl, University of Wu¨rzburg, Germany) (Fig 1). Interest-
ingly, the EGF receptor could not be detected beyond 30
min after the addition of recombinant EGF, being consistent
with EGF receptor-mediated endocytosis and ubiquitination
(Dikic, 2003). An alternative explanation is the increased
degradation of internalized EGF receptors following treat-
ment with recombinant EGF (Dikic, 2003). Western blot
analysis is much more sensitive than flow cytometry (Kao
and Yu, 1992) or radioactive binding studies using 125I-EGF
(Greenebaum et al, 1983) that have been previously used to
analyze the presence of EGF receptors on NHM.
Moreover, we used northern blot analysis on total RNA
from NHM (Fig 2) (Hassan et al, 2004) and real-time PCR to
demonstrate EGF receptor transcripts (Fig 3). Although
Figure1
Western blot of epidermal growth factor (EGF) receptor expression
and JAK/STAT signaling in normal human melanocytes (NHM) and
A375 cells. EGF receptors were detectable in protein extracts from
cultured NHM without and upon treatment with 100 ng per mL recom-
binant EGF, respectively. EGF receptors were present at high levels for
15 min, with levels decreasing thereafter in both NHM (A) and A375
cells (B). Interestingly, JAK2 and STAT5 phosphorylation occurred in
NHM between 1 and 30 min following stimulation with recombinant
EGF (A), whereas in A375 cells, JAK1 and SRC became phosphory-
lated parallel to STAT5 (B) (manuscript in preparation).
Abbreviation: EGF, epidermal growth factor; NHM, normal human
melanocytes
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northern blot analysis has previously served to detect EGF
receptor transcripts (Chenevix-Trench et al, 1990), real-time
PCR has, to our knowledge, not been utilized to analyze
EGF receptors on NHM. On average, EGF receptor levels in
six primary melanoma and eight cutaneous metastases
were 13.3-fold higher compared with NHM (p¼ 0.043).
Since EGF is known to signal via the JAK/STAT pathway,
we assessed signal transduction in NHM (Fig 1A) and A375
cells (Fig 1B) following the addition of 100 ng per mL of
recombinant EGF using antibodies against P-JAK2, P-
STAT3, and P-STAT5 (P-JAK-2, Cat. Nr. 44–426G; P-STAT5,
BD Biosciences Pharmingen, Cat. Nr. 611965; and P-
STAT3, BD Biosciences Pharmingen (Heidelberg, Germany),
Cat. Nr. 612356). As shown, EGF receptor signaling in NHM
seemed to involve the activation of JAK-2. Parallel to EGF
receptor signaling, STAT5 became phosphorylated in both
cell types (Fig 1). Exclusively in NHM, weak STAT3 phos-
phorylation also occurred (Fig 1A).
Next, we assessed cell growth by the 5-bromo-20-deoxy-
uridine (BrdU) proliferation assay following stimulation of
NHM with recombinant EGF (Fig 4; Mirmohammadsadegh
et al, 1998). Proliferation increased by 100% (po0.05),
whereas the JAK inhibitor AG490 (50 mM) or the MEK in-
hibitor U0126 (25 mM) alone or in combination reduced pro-
liferation by 60%–80% (Fig 4). Recombinant EGF did
not rescue cellular proliferation in the presence of these
inhibitors.
To corroborate the finding of EGF-induced signaling via
the JAK/STAT pathway, as has been demonstrated in fib-
roblasts by Kloth et al (2003), the SRC inhibitors PP1 and
PP2 (each obtained from Sigma-Aldrich, Tauf Kirchen,
Germany) were added to NHM 3 h prior to the addition of
100 ng per mL recombinant EGF (Fig 5). When the SRC
inhibitors were used alone or in combination, only weak P-
STAT5 signals were detected in comparison with the EGF
control (Fig 5), indicating that SRC non-receptor typrosine
kinases in addition to JAK2 (Fig 1A) represent the main kin-
ases in EGF receptor-mediated activation of STAT5.
In conclusion, our results show that EGF receptors are
present on NHM using various independent techniques
(immunocytochemistry, western blot, northern blot, and re-
al-time PCR). Furthermore, signaling in NHM seems to oc-
cur via JAK2 and SRC non-receptor tyrosine kinases
causing phosphorylation of STAT5, whereas in A375 cells,
SRC, and JAK1 were responsible (manuscript in prepara-
tion). Our results also support the integral role of SRC in the
physiological action of STAT5 (i.e. mediation of EGF-in-
Figure 2
Northern blot of epidermal growth factor (EGF) receptor expres-
sion. RNA was obtained from cultured normal human melanocytes
stimulated with recombinant EGF for up to 5 h and hybridized with a
32P-labeled EGF receptor probe. Hybridization showed constitutive and
constant expression of EGR receptors relative to the housekeeping
gene GAPDH, suggesting translational regulation.
Figure 3
Epidermal growth factor (EGF) receptor real-time PCR. Lesional
tissue from six primary melanomas, eight cutaneous metastases, and
two benign nevi was used for RNA extraction upon microscope-guided
excision. EGF receptor transcripts levels are shown in relation to nor-
mal human melanocytes (NHM). The average transcript level was 13.3-
fold higher (p¼0.043) than in NHM, with no significant difference being
observed between metastases and primary tumors. SSM: superficial
spreading melanoma; ALM: acral lentiginous melanoma; NM: nodular
melanomo.
Figure4
Proliferation analysis of normal human melanocytes (NHM) in re-
sponse to recombinant epidermal growth factor (EGF) and several
signaling inhibitors. Proliferating cells were quantified using the 5-
bromo-20-deoxy-uridine proliferation assay prior to and 24 h after the
addition of 100 ng per mL recombinant EGF. Although recombinant
EGF increased proliferation by 100% (n¼3), inhibitors of the JAK/STAT
and MAP kinase pathways reduced growth between 60% and 80%.
Recombinant EGF was not able to override the effect of either or both
inhibitors.
Figure5
SRC non-receptor typrosine kinases can also mediate epidermal
growth factor (EGF) receptor-mediated STAT5 activation. The non-
receptor tyrosine kinase SRC was inhibited by adding the SRC inhib-
itors PP1 and PP2 (each 10 mM), resulting in significantly reduced levels
of P-STAT5. Recombinant EGF was added 15 min prior to preparing the
protein extracts for Western blot analysis.
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duced DNA synthesis and proliferation) that has been de-
scribed in fibroblasts and breast cancer (Kloth et al, 2003).
Therefore, our results are in contrast to the findings by
Grahn and Isseroff and are in accordance with the report by
Gordon-Thomson et al (2001), Stove et al (2003) and the
most recent publication by Ivanov and Hei (2005). In future
experiments, the target genes of active EGF-signaling in
melanoma need to be identified. The findings warrant fur-
ther studies on the potential usefulness of EGF receptor
antibodies and protein tyrosine kinase inhibitors in me-
lanoma that have recently been licensed for treating epi-
thelial cancers.
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